Cargando…
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
BACKGROUND: Non-small cell lung cancer (NSCLC) harboring activating mutations in the gene encoding epidermal growth factor receptor (EGFR) is amenable for targeted therapy with tyrosine kinase inhibitors (TKIs). Eventually, resistance to TKI-therapy occurs resulting in disease progression. A substan...
Autores principales: | Kaźmierczak, Dominika, Eide, Inger Johanne Zwicky, Gencheva, Radosveta, Lai, Yi, Lewensohn, Rolf, Tsakonas, Georgios, Grundberg, Oscar, de Petris, Luigi, McGowan, Marc, Brustugun, Odd Terje, Ekman, Simon, Hydbring, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186160/ https://www.ncbi.nlm.nih.gov/pubmed/35693293 http://dx.doi.org/10.21037/tlcr-21-955 |
Ejemplares similares
-
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
por: Alexeyenko, Andrey, et al.
Publicado: (2022) -
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
por: Kosibaty, Zeinab, et al.
Publicado: (2022) -
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023) -
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022) -
“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
por: Dyrbekk, Anne Pernille Harlem, et al.
Publicado: (2023)